By precisely blocking this signaling pathway, PD-1/PD-L1 inhibitors—such as pembrolizumab (99) and cemiplimab (100)—have been shown to successfully restore the antitumor function of T cells, enabling them to regain activity and mount effective attacks against Tumor Cells (101). Here, CD274 is linked to neoplasm.